



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

GF/B22/16
For information

ELECTRONIC DECISION POINTS 7 May 2010 - 10 December 2010

PURPOSE:

This paper provides a copy of the Board's decisions that were taken electronically between the adjournment of the Twenty-First Board Meeting and the start of the Twenty-Second Board Meeting.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Criteria for Exceptions to the Salary Threshold

Confirmed 7 May 2010

Decision Point GF/B21/EDP/01:

The Board refers to GF/B21/DP10 and decides that in cases where an exception is sought to the threshold, the Remuneration Group shall consider approval based on written justification provided by the Executive Director as specified below:

- i) An explanation as to how the selection of the Grade and positioning in the band of the proposed salary has been established according to the Global Fund's remuneration policy and procedures.
- ii) A comprehensive rationale as to why this exceptional salary is deemed necessary and appropriate based on the candidate's professional qualifications, experience, comparison with the market or other specific qualifications. The rationale may also include, as necessary, managerial considerations that relate to the specific needs of the Secretariat.
- iii) An explanation of the efforts that have been undertaken to identify qualified alternative candidates that may have accepted a salary below the threshold or justify why such efforts were not deemed possible and/or appropriate.
- iv) A risk assessment addressing the potential negative impact of approval of the salary, including the risk of setting a precedent, creating a trend towards a general increase in the levels of remuneration and the potential reputational risks for the Global Fund.

This decision does not have material budgetary implications



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

May 2010 Phase 2 Funding Decision

Confirmed 14 May 2010

Decision Point GF/B21/EDP/02:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).¹

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Kenya, TB, Round 6	KEN-607-G08-T	US\$ 4,334,614	US\$ 3,444,603	Conditional Go
2.	Sierra Leone, Malaria, Round 7	SLE-708-G05-M	US\$ 14,488,057	US\$ 12,637,442	Conditional Go
3.	Somalia, TB, Round 7	SOM-708-G05-T	US\$ 20,022,103	US\$ 17,943,511	Go
Total				US\$ 34,025,556	

This decision does not have material budgetary implications.

¹ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

**Secretariat's request to the Board with respect to an extension of time to fulfill a
'Condition' - Gabon**

Confirmed 14 May 2010

Decision Point GF/B21/EDP/03:

The Board acknowledges that, due to unforeseen delays in program implementation as well as political disturbances in Gabon, the condition 1b. upon which the Board approved the Round 5 malaria grant to the Government of Gabon (GAB-509-G04-M) will not be fulfilled by its current deadline of 19 May 2010. The Board decides to revise this condition 1b to read: "Within 16 months of signing the Phase 2 extension, a Global Fund internal performance review shall be carried out to assess programmatic and management (including financial) performance of the grant. If the results of this review are not satisfactory to the Global Fund, the grant shall be terminated."

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

June 2010 Phase 2 Funding Decision

Confirmed 14 June 2010

Decision Point GF/B21/EDP/04:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).²

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Benin, Malaria, Round 7	BEN-708-G07-M	Euros 7,056,927	Euros 2,809,045 = US\$ 3,455,240 *	Conditional Go
2.	Bhutan, Malaria, Round 7	BTN-708-G05-M	US\$ 1,268,060	US\$ 905,938	Conditional Go
3.	Cote d'Ivoire, Malaria, Round 6	CIV-607-G06-M	Euros 5,765,695	Euros 3,348,647 = US\$ 4,118,970 **	Go
4.	Lesotho, HIV, Round 7	LSO-708-G05-H	US\$ 20,224,887	US\$ 15,249,526 ***	Conditional Go
5.	Nepal, TB, Round 7	NEP-708-G08-T	US\$ 9,145,040	US\$ 8,815,424	Go

² Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
6.	Niger Malaria, Round 7	NGR-708-G07-M	Euros 6,038,018	Euros 5,914,863 = US\$ 7,275,520*	Go
7.	Mali, Malaria, Round 6	MAL-607-G04-M	US\$ 3,669,912	US\$ 3,604,863	Conditional Go
8.	Mongolia, HIV, Round 7	MON-708-G05-H	US\$ 1,359,539	US\$ 1,349,344	Go
9.	Multi- Country Western Pacific, TB, Round 7	MWP-708-G07-T	US\$ 7,344,790	US\$ 5,625,579	Go
10.	Paraguay TB, Round 7	PRY-708-G03-T	US\$ 3,481,687	US\$ 3,427,420	Go
11.	Senegal, Malaria, Round 7	SNG-708-G07-M	Euros 20,836,866	Euros 15,032,313= US\$ 18,490,300 *	Conditional Go
12.	Thailand, Malaria, Round 7	THA-708-G09-	US\$ 10,425,580	US\$ 9,282,734	Conditional Go
Total				US\$ 81,600,858	

NOTES:

(*) The Malaria proposals for Benin, Cote d'Ivoire, Niger and Senegal were approved in Euros and the CCM has requested Phase 2 funding in Euro currency. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 1 June 2010 (Euro1 = US\$1.23004).

(**) The Secretariat determined that due to weak management by the PR (primarily oversight of SRs) the grant should receive a 'No Go' recommendation. However, in its request the CCM had requested that two PRs take on the Phase 2 implementation, including PNLP. It is the view of the Secretariat that the 'No Go' derives from poor management and not from poor results of the program per se. Therefore the Secretariat recommends that the portion of the program and budget allocable to PNLP should be allowed to continue, whilst that under the management of CARE will be discontinued. The Secretariat is not requesting any incremental amount for CARE.

(***) This incremental amount of US\$ 15,249,526 excludes the funds which may be requested by the CCM at the later date to support the National Prevention of Mother-to-Child Transmission (PMTCT) efforts which has been encouraged by the Board.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Additional funding for Continuity of Services for Papua New Guinea (PNG-405-G02-H)

Confirmed 14 June 2010

Decision Point GF/B21/EDP/05:

The Board approves additional funding for up to two years for the Continuity of Services for the proposal listed in Schedule B, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)
1.	Papua New Guinea, HIV, Round 4	PNG-405-G02-H	US\$ 6,443, 553	US\$ 1,856,418
	Total			US\$ 1,856,418

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

July 2010 Phase 2 Funding Decision

Confirmed 15 July 2010

Decision Point GF/B21/EDP/06:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).³

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Liberia, TB, Round 6	LBR-708-G06-T	US\$ 8,665,641	US\$ 7,056,465	Conditional Go
2.	Guinea, HIV Round 6	GIN-607-G04-H	US\$ 15,446,682	US\$ 13,070,938	Conditional Go
Total				US\$ 20,127,403	

This decision does not have material budgetary implications.

³ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of the Phase 2 term and additional funds for the Republic of Suriname (SUR-404-G02-M)

Confirmed 15 July 2010

Decision Point GF/B21/EDP/07:

The Board acknowledges that, due to circumstances which were mainly beyond the control of the CCM, the PR has not been given adequate opportunity to prepare for the orderly close out of the Program. Although the criteria for Rolling Continuation Channel (RCC) Bridge Funding do not apply to the circumstances of this grant, the Board approves, as an exception, additional funding amounting to US\$ 254,559 and additional time for the PR to implement the grant up to 31 October 2010.

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)
1.	Republic of Suriname	SUR-404-G02-M	US\$ 529,102	US\$ 254,559
	Total			US\$ 254, 559

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Waiver of a 'Condition' - Niger (NGR-506-G04-M and MGR-506-G05-T)

Confirmed 15 July 2010

Decision Point GF/B21/EDP/08:

The Board acknowledges that, due to serious governance issues at the Ministry of Public Health, frequent changes of the Minister and a volatile political situation in Niger the condition upon which the Board approved the Round 5 malaria and tuberculosis grants to the United Nations Development Program (NGR-506-G04-M and NGR-506-G05-T) has not been fulfilled. However, the Board decides to waive this condition in light of the context in Niger.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of the Rolling Continuation Channel (RCC) Phase 1 Term for the Rwanda Round 3 (RWN-304-G03-M)

Confirmed 15 July 2010

Decision Point GF/B21/EDP/09:

The Board acknowledges that the Secretariat intends to use the new Grant Score Card which is being developed for the Periodic Review under the New Architecture for future RCC Mid-term Performance Reviews. In order to allow sufficient time for the Rwanda Round 3 RCC Malaria grant (RWN-304-G03-M) to be reviewed under the new Grant Score Card and, if approved for further funding by the Board, to allow sufficient time for the grant to be negotiated and signed, the Board approves a six month no cost extension to the RCC Phase 1 term of the grant so that the term shall now expire on 1 April 2011.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Approval of the Final Resubmission Wave of RCC Proposals

Confirmed 4 August 2010

Decision Point GF/B21/EDP/10:

1. The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposal recommended for funding by the Technical Review Panel (TRP) as 'Category 2' which is listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for the Final Resubmission Wave of Rolling Continuation Channel Proposals (the "Final Resubmission Wave RCC Report"). The Board approves funding for up to three years for the proposal (indicated as "Total 3 Years" in Annex 1 to the Final Resubmission Wave RCC Report). The Board's approval is made with the clear understanding that the grant amount requested is an upper ceiling subject to TRP clarifications and grant negotiations rather than a final approved grant amount. For further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.
2. The applicant whose proposal is recommended for funding as 'Category 2' shall:
 - i. provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board's decision; and
 - ii. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.
3. The Board declines to approve for funding proposals categorized by the TRP as 'Category 3B' as indicated in Annex 1 to the Final Resubmission Wave RCC Report. Such applicants are encouraged to submit a revised proposal through the Rounds-Based Channel, taking into account the TRP's recommendations. The Board approves, on an exceptional basis, a two week extension of the Round 10 submission deadline (i.e. to 3 September 2010) for such applicants.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Exceptional Extension to the Round 10 Submission Deadline

Confirmed 4 August 2010

Decision Point GF/B21/EDP/11:

The Board approves, on an exceptional basis, a two week extension of the Round 10 proposal submission deadline (i.e. to 3 September 2010) for the following Country Coordinating Mechanisms, whose Rolling Continuation Channel (RCC) proposals were not approved for funding as part of the Final RCC Resubmission Wave, to submit a Round 10 proposal for HIV/AIDS:

- Burundi;
- Tanzania; and
- Togo.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of Grant Signing Deadline for Haiti Round 8 Malaria Proposal

Confirmed 10 August 2010

Decision Point GF/B21/EDP/12:

The Board extends the deadline for the signing of the Round 8 Haiti Malaria Proposal to 11 February 2011.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

August 2010 Phase 2 Funding Decision

Confirmed 15 August 2010

Decision Point GF/B21/EDP/13:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁴

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Pakistan, Malaria, round 7	PKS-708-G08-M	US\$ 6,408,736	US\$ 6,878,438	Go
2	Pacific Islands Regional Multi- Country Coordinating Mechanism	MWP-708-G06-H	US\$ 13,976,096	US\$ 10,848,326	Go
3	Jamaica, HIV, Round 7	JAM-708-G02-H	US\$ 25,492,038	US\$ 24,771,121	Go
4	Niger, HIV, Round 7	NGR-708-G08-H	Euros 16,326,012	Euros 16,326,012 = US\$21,414,800	Go
5	Liberia, Malaria, Round 7	LBR-708-G05-M	US\$ 25,021,843	US\$ 20,927,976.	Conditional Go
Total				US\$ 84,840,661	

⁴ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

NOTES:

(*) The HIV proposal for Niger was approved in Euros and the CCM has requested Phase 2 funding in Euro currency. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 3 August 2010 (Euro1 = US\$1.31170).

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

**The Technical Review Panel (TRP) recommendation to commit additional funding for
Lao PDR (LAO-708-G09-M)**

Confirmed 15 August 2010

Decision Point GF/B21/EDP/14:

The Board approves additional funding for the Phase 2 period of the Round 7 Lao PDR Malaria grant (LAO-708-G09-M) as a 'Conditional Go' in the amount of up to US\$ 15,390,435, subject to TRP clarifications and conditions within a limited timeframe. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its regular performance-based evaluation criteria.

The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Declination to approve additional funding for Sri Lanka (SRL-607-G08-T)

Confirmed 15 August 2010

Decision Point GF/B21/EDP/15:

The Board declines approval of additional funding for the Phase 2 period for the Round 6 Sri Lanka TB grant (SRL-607-G08-T).

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)
1.	Sri Lanka TB, Round 6	SRL-607-G08-T	US\$ 875,515	No additional funding

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Approval of Equatorial Guinea Continuity of Services request (GNQ-405-G01-H)

Confirmed 15 August 2010

Decision Point GF/B21/EDP/16:

The Board acknowledges that, while Equatorial Guinea is classified as high income country according to the World Bank income classification and therefore no longer eligible for Global Fund support, the CCM requires additional time to mobilize resources for the Continuity of Services (CoS) for the 2,330 patients currently on life-saving treatment. The Board therefore approves the funding from the Phase 2 undisbursed funds of the Equatorial Guinea Round 4 HIV grant in the amount of USD 765,674, for the one year period from 1 July 2010 until 30 June 2011, with the understanding that not later than 31 December 2010, the CCM will submit to the Global Fund a transition plan identifying how the patients on treatment will be funded from government and other sources after the end of the one year period approved for CoS.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of time to fulfil a 'Condition' - Multi-Country Africa (MAW-607-G01-H)

Confirmed 15 August 2010

Decision Point GF/B21/EDP/17:

The Board refers to condition number 2 in its decision approving as a 'Conditional Go' the Phase 2 of the Round 6 HIV grant of Multi-Country Africa (MAW-607-G01-H) ("Condition 2") which states that: "Not later than 31 August 2010 and based on programmatic and financial data from 30 months of implementation (ie 28 Feb 2010) an independent evaluation of the program should be conducted to assess: a) the effectiveness and efficiency of the program activities, including M&E activities - compared with having the same activities funded under the national programs; b) the regional coordinating mechanism that has been put in place to allow patients to be transferred to different sites to access treatment in a coordinated way across the 5 countries; and, c) whether the grant activities and budget overlap with, duplicate, or are complementary to activities and funding covered by national programs. Funding for Years 4 and 5 of the program shall be subject to the Global Fund's satisfactory review of the results of the evaluation."

The Board decides to extend the deadline in Condition 2 from 31 August 2010 to 17 October 2010 to allow the Secretariat adequate time to review the independent evaluation report.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Technical Review Panel Recruitment 2010-2012

Confirmed 20 August 2010

Decision Point GF/B21/EDP/18:

The Board approves the appointment of the following:

1. Anupong Chitwarakorn (HIV/AIDS), Stephen Mills (HIV/AIDS), Anthony David Harries (Tuberculosis), Frank Aday Bonsu (Tuberculosis), Daniel Tarantola (Cross-cutting), Mari Nagai (Cross-cutting), Lev Khodakevich (Cross-cutting), Claudia Surjadaja (Cross-cutting) and Lucie Blok (Cross-cutting) as Permanent Technical Review Panel (TRP) Members to serve for up to four Rounds commencing from Round 10;
2. In respect of Round 10, the twenty (20) persons identified as Alternate Members as presented in Annex 1 of this Report (B21/EDP/18); and
3. The membership of the Technical Review Panel Support Group (as presented in Annex 1 of this Report (B21/EDP/18)), comprising the pool of experts from which TRP membership will be replenished in the event of TRP vacancies as they may arise.

Each Permanent TRP, Alternate and Support Group Member has been recommended by the Portfolio and Implementation Committee and the Executive Director of the Global Fund Secretariat.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Approval of Russian Federation Continuity of Services (RUS-405-G03-H)

Confirmed 1 September 2010

Decision Point GF/B21/EDP/19:

1. The Board acknowledges that while the Russian Federation does not meet all the eligibility criteria for Global Fund support for upper middle income countries:
 - a. there is a need for continuing ARV treatment for 12,258 patients currently on treatment for the three month period (September - November 2010) who are being transitioned into the National Program; and
 - b. the Russian Federation also requires additional time to finalize the transition of ARV treatment of 4669 migrants and prisoners into the National Treatment Program.
2. The Board therefore approves an incremental amount of US\$ 16,623,895 with the understanding that by not later than 31 March 2011, the CCM will submit to the Global Fund a transition plan for migrants and prisoners describing how the patients on treatment will be funded from Government and other sources after the end of one year period approved for Continuity of Services (1 September 2010 to 31 August 2011).

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Multi-Year Contributions and Promissory Notes from Private Donors

Confirmed 10 September 2010

Decision Point GF/B21/EDP/20:

The Board refers to its decision at its Twenty-First Meeting, which requested the Finance and Audit Committee (FAC) to conduct a review of the Global Fund Comprehensive Funding Policy (CFP) (GF/B21/DP13). It also notes the issues raised in the report of the FAC Working Group on the Review of the Comprehensive Funding Policy (GF/FAC15/08) and its associated annexes.

The Board notes the importance of increasing the level of assurance and predictability of donor funding to the Global Fund, promoting inter-donor equity and ensuring that donor funding is used as effectively as possible for the benefit of people in need. In this context, the Board notes the need for formalization of donor commitments made through the replenishment process.

The Board decides that in order to increase the level of assurance and predictability of donor commitments following the announcement of pledges, while taking into consideration the budgetary systems of individual donors, the Secretariat should seek to conclude multi-year contribution agreements between individual donors and the Global Fund. The Board agrees that such multi-year contribution agreements should, as appropriate, be developed on the basis of the principles outlined in GF/FAC15/08 Annex 3.

The Board notes that the conclusion of multi-year contribution agreements does not require amendment to the CFP. However, the FAC and the Working Group will pursue the review of the CFP to ensure donor funding is used as effectively as possible for the benefit of people in need, while maintaining appropriate levels of financial assurance. The FAC will present any recommended changes thereto, beyond those set out below, to the Board for decision at its Twenty-Second Meeting.

The Board notes Annex 5 to GF/FAC15/08, entitled “The CFP and Promissory Notes from Private Donors”, and decides to replace paragraph 4 of the CFP as follows:

The Global Fund shall consider as assets for the purposes of entering into grant agreements the following: cash; promissory notes or similar obligations issued by the government of a sovereign state (or its designated depository); and, subject to approval by the Finance and Audit Committee, promissory notes or similar obligations issued by private donors. For these purposes, promissory notes and similar obligations shall be non-negotiable, non-interest bearing and payable at par value to the account of the Global Fund in the designated depository on demand or in accordance with an encashment schedule agreed on between the contributor and the Secretariat.

There are no material budgetary implications to this decision point.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

September Phase 2 decision to commit additional funding for the proposals listed in Schedule A

Confirmed 21 September 2010

Decision Point GF/B21/EDP/21:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁵

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Multi-Country Americas (REDCA+), HIV, Round 7	MAR-708-G01-H	US\$ 3,828, 650	US\$ 3,638,650	Go
2	Burundi, HIV, Round 7	BRN-708-G06-T	US\$ 5,373,999	US\$ 5,599,076	Go

⁵ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
3.	Azerbaijan, Malaria, Round 7	AZE-708-G04-M	Euro 1,852,158	Euro 1,497,249 * = US\$ 1,902,704	Go
4.	Azerbaijan, TB, Round 7	AZE-708-G03-T	Euro 14,301,496	Euros 9,448,527 = US\$ 12,007,188 *	Conditional Go
5.	Lao PDR, TB, Round 7	LAO-708-G10-T	US\$ 5,917,326	US\$ 5,319,382	Conditional Go
6	Kosovo, HIV, Round 7	KOS-708-G02-H	Euro 2,930,116	Euro 2,481,556 * = US\$ 3,153,561	Go
7	Rwanda HIV, Round 7	RWN-708-G09-H	US\$ 66,666,116	US\$ 65,279,925	Go
Total				US\$ 96,900,486	

NOTES:

(*) These proposals were approved in Euros and the CCM has requested Phase 2 funding in Euro currency. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 10th September 2010 (Euro 1 = US\$ 1.2708).

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

October Phase 2 decision to commit additional funding for the proposals listed in Schedule A

Confirmed 15 October 2010

Decision Point GF/B21/EDP/22:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁶

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	India, HIV, Round 7	IDA-708-G13-H	USD 25,676,072	US \$ 25,858,390	Go
2	India, HIV, Round 7	IDA-708-G14-H	USD 15,023,348	US \$ 12,486,620	Go
3	India, HIV, Round 7	IDA-708-G15-H	USD 11,354,703	US \$ 7,671,916	Conditional Go
4	Cambodia, HIV, Round 7	CAM-708-G11-H	USD 19,403,180	US \$ 13,651,352	Go
5	Malawi, HIV, Round 7	MLW-708-G07-H	USD 15,803,767	US\$ 15,003,832	Go
6	Uganda, TB, Round 6,	UGD-607-G06-T	USD 8,483,248	US \$ 5,802,086	Conditional Go

⁶ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
7	Dominican Republic, TB Round 7	DMR-708-G03-T	USD 4,225,154	US \$ 4,241,903	Conditional Go
8	Senegal, TB, Round 7	SNG-708-G08-T	Euro 2,690,022	Euro 2,541,655 = US \$ 3,462,496	Go
	Total			USD 88,178,595	

(*) The tuberculosis proposal for Senegal was approved in Euros and the CCM has requested Phase 2 funding in Euro currency. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 1 October 2010 (Euro1 = US\$ 1.3623).

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

The Secretariat's request to the Board not to commit additional funding for the Phase 2 term of Round 6 Zanzibar HIV grant (ZAN-607-G06-H)

Confirmed 15 October 2010

Decision Point GF/B21/EDP/23:

The Board declines approval of additional funding for the Phase 2 period for the Round 6 Zanzibar HIV grant (ZAN-607-G06-H)

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)
1.	Zanzibar, HIV, Round 6	ZAN-607-G06-H	USD 309,671	No additional funding

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Additional funding for Nigeria (NGA S10-G17-H)

Confirmed 24 October 2010

Decision Point GF/B21/EDP/24:

The Board approves additional funding for the Phase 1 period of the Round 9 Nigeria HIV/AIDS proposal to accelerate the scale-up of prevention of mother-to-child transmission interventions in the amount of up to US\$ 29,325,424 subject to TRP clarifications and conditions within a limited timeframe. Approval is given for this amount on the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and is based on the understanding that the overall life-time budget for the proposal of US\$ 341,019,908 does not change by this Decision.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of Timeline: Procedure for Appointment of Executive Director

Confirmed 31 October 2010

Decision Point GF/B21/EDP/25:

In order to allow adequate time for further in-person consultations during the Executive Session of the Twenty-Second Board Meeting, the Board agrees, on an exceptional basis, to postpone, by approximately six weeks, the deadline for reaching a decision on the next steps pertaining to the Executive Director's term of office.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Extension of Grant Signing Deadlines: Round 9 and AMFm Proposals

Confirmed 10 November 2010

Decision Point GF/B21/EDP/26:

The Board extends the deadline for the signing of grant documentation for the proposals listed in Annex A for three months to 10 February 2011.

The Board also extends the Phase 2 Period of the AMFm host grant in Uganda (UGD-405-G5-M) until 10 February 2011 and authorizes the host grant activities specified for that grant in Annex A to be implemented.

There are no material budgetary implications of this decision.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

November Phase 2 decision to commit additional funding for the proposals listed in Schedule A

Confirmed 19 November 2010

Decision Point GF/B21/EDP/27:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁷

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A *

**Refer to GF/B21/EDP/32 below for a correction to Schedule A for the grants listed at numbers 10 and 11.*

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Nepal, Malaria, Round 7	NEP-708-G06-M	US\$10,676,236	US\$ 9,859,767	Go
2	Iran, Malaria, Round 7	IRN-708-G02-M	US\$4,872,994	US\$ 4,600,968	Go
3	Iran, TB, Round 7	IRN-708-G03-T	US\$9,948,454	US\$ 6,305,126	Go

⁷ The Phase 2 Panel reviewed the Zambia grants in the light of the findings in the recently published OIG audit report of the Country and the measures put forward by the Secretariat to address those findings. Following representations made by the Country Team on its proposed strategy to manage the portfolio of grants in the Country going forward as well as balancing the issues raised by the key weaknesses in grant management and performance by the Principal Recipients, the Phase 2 Panel was able to make the above recommendations to the Board for continued funding in order to find a constructive way forward for the Country.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
4	Sierra Leone, TB, Round 7	SLE-708-G03-T	US\$5,170,647	UD\$ 4,885,388	Conditional Go
5	Sudan, Malaria, Round 7	SUD-708-G09-M	US\$38,510,162	US\$ 37,909,471	Go
6	Madagascar, Malaria, Round 7	MDG-708-G09-M	US\$25,097,417	US\$ 16,462,000	Conditional Go
7	Afghanistan, HIV, Round 7	AFG-708-G04-H	US\$917,425	US\$ 483,579	Conditional Go
8	Afghanistan, HIV, Round 7	AFG-708-G05-H	US\$3,969,750	US\$ 3,157,640	Go
9	Zambia, TB, Round 7*	ZAM-708-G16-T	US\$25,670,852	US\$ 9,015,288	Conditional Go
10	Zambia, TB, Round 7*	ZAM-708-G18-T	US\$7,548,518	US\$ 818,664	Conditional Go
11	Zambia, Malaria, Round 7*	ZAM-708-G17-M	US\$2,437,280	US\$ 2,437,280	Conditional Go
12	Zambia, Malaria, Round 7*	ZAM-708-G19-M	US\$3,751,567	US\$ 2,379,990	Conditional Go
13	Guinea, Malaria, Round 6	GIN-607-G05-M	US\$9,639,532	US\$ 4,062,054	Conditional Go
	Total			US\$ 102,377,215	

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Increase to the 2010 Budget of the Office of the Inspector General

Confirmed 25 November 2010

Decision Point GF/B21/EDP/28:

The Board decides to approve an increase of US \$1,923,339 to the 2010 Budget of the Office of the Inspector General bringing the total budget of the Office of the Inspector General for 2010 to \$12,227,621.

The increase in the budget for the Office of the Inspector General will be absorbed from within the existing 2010 Operating Expenses Budget.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Phase 2 December 2010

Confirmed 10 December 2010

Decision Point GF/B21/EDP/29:

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).¹
2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

No	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Cuba, TB, Round 7	CUB-708-G03-T	USD 2,022,290	US\$ 2,072,290	Go
2	Yemen, Malaria, Round 7	YEM-708-G06-M	USD 17,734,937	US\$17,782,038	Go
3	Nepal, Malaria, Round 7	NEP-708-G07-M	USD 2,195,897	US\$1,766,908	Go
4	Nepal, HIV, Round 7	NEP-708-G09-H	USD 11,852,088	US\$11,101,993	Go
5	Nepal, HIV, Round 7	NEP-708-G10-H	USD 5,452,806	US\$5,352,809	Go
6	Nepal, HIV, Round 7	NEP-708-G11-H	USD 5,299,945	US\$5,128,214	Go
7	Timor-Leste, TB, Round 7	TMP-708-G04-T	USD 3,896,222	US\$ 3,409,910	Conditional Go
8	Vietnam, Malaria, Round 7	VTN-708-G06-M	USD 13,761,420	US\$ 11,244,413	Conditional Go



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

No	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
9	Ethiopia, HIV, Round 7	ETH-708-G09-H	USD 16,375,496	USD 16,375,496	Conditional Go
10	Malawi, Malaria, Round 7	MLW-708-G05-M	USD 34,897,253	US\$ 32,336,860	Conditional Go
11	Kazakhstan, HIV Round 7	KAZ-708-G03-H	USD 22,387,043	USD 18,056,731	Go
12	Sudan, TB, Round 7	SUD-708-G11-T	USD 8,636,721	US\$ 8,544,198	Go
				US\$ 133,171,860	

This decision does not have material budgetary implications.

¹ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Additional funding for Round 7 Lesotho HIV grant (LSO-708-G05-H)

Confirmed 10 December 2010

Decision Point GF/B21/EDP/30:

The Board approves additional funding up to US\$ 4,998,103 for the Phase 2 period of the Round 7 Lesotho HIV grant (LSO-708-G05-H) to improve the quality and scale of PMTCT activities, subject to TRP clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US\$ 20,247,629 which includes an additional sum of US\$ 4,998,103 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

Discontinuation of funding for the Gabon Round 5 Malaria grant (GAB-509-G04-M)

Confirmed 10 December 2010

Decision Point GF/B21/EDP/31:

The Board acknowledges that the condition upon which the Board approved continued funding to Gabon Round 5 Malaria grant (GAB-509-G04-M) to the Ministry of Health and Public Hygiene of Gabon required the Principal Recipient to achieve a satisfactory level of performance within sixteen months of signature of the Phase 2 Grant Agreement. Recognizing that the condition has not been fulfilled, the Board decides to discontinue funding for the remaining period of the grant and requests the Secretariat to close out the grant in accordance with its delegated authority for Grant Closure Activities (GF/B17/DP6).

This decision does not have material budgetary implications.



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-Second Board Meeting
Geneva, 13-15 December 2010

The Secretariat's recommendation to replace the funding ceilings for the November Phase 2 decisions for Zambia (GF/B21/EDP27) with corrected funding ceilings

Confirmed 10 December 2010

Decision Point GF/B21/EDP/32:

Referring to its earlier decision on 23 November 2010 (GF/B21/EDP27), the Board:

1. Notes a transcription error was made in the reporting of the amounts requested and the Secretariat's recommendation for incremental funding for the Phase 2 period for the Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M listed in Schedule A of that earlier decision point.
2. Decides to amend its funding decision for the two Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Schedule A to this decision point, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).¹
3. Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

This decision does not have material budgetary implications.

SCHEDULE A

No	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Nepal, Malaria, Round 7	NEP-708-G06-M	US\$10,676,236	US\$ 9,859,767	Go
2	Iran, Malaria, Round 7	IRN-708-G02-M	US\$4,872,994	US\$ 4,600,968	Go
3	Iran, TB, Round 7	IRN-708-G03-T	US\$9,948,454	US\$ 6,305,126	Go



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

**Twenty-Second Board Meeting
Geneva, 13-15 December 2010**

No	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
4	Sierra Leone, TB, Round 7	SLE-708-G03-T	US\$5,170,647	UD\$ 4,885,388	Conditional Go
5	Sudan, Malaria, Round 7	SUD-708-G09-M	US\$38,510,162	US\$ 37,909,471	Go
6	Madagascar, Malaria, Round 7	MDG-708-G09-M	US\$25,097,417	US\$ 16,462,000	Conditional Go
7	Afghanistan, HIV, Round 7	AFG-708-G04-H	US\$917,425	US\$ 483,579	Conditional Go
8	Afghanistan, HIV, Round 7	AFG-708-G05-H	US\$3,969,750	US\$ 3,157,640	Go
9	Zambia, TB, Round 7*	ZAM-708-G16-T	US\$25,670,852	US\$ 9,015,288	Conditional Go
10	Zambia, TB, Round 7*	ZAM-708-G18-T	US\$7,548,518 US\$ 3,817, 574	US\$ 818,664 US\$ 2,437,280	Conditional Go
11	Zambia, Malaria, Round 7*	ZAM-708-G17-M	US\$2,437,280 US\$ 7,548,518	US\$ 2,437,280 US\$ 818,664	Conditional Go
12	Zambia, Malaria, Round 7*	ZAM-708-G19-M	US\$3,751,567	US\$ 2,379,990	Conditional Go
13	Guinea, Malaria, Round 6	GIN-607-G05-M	US\$9,639,532	US\$ 4,062,054	Conditional Go
	Total			US\$ 102,377,215	

¹ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.